Involvement of CCAAT/enhancer-binding protein and nuclear factor-kappa B binding sites in interleukin-6 promoter inhibition by estrogens

被引:102
作者
Galien, R [1 ]
Evans, HF [1 ]
Garcia, T [1 ]
机构
[1] ROUSSEL UCLAF, F-93235 ROMAINVILLE, FRANCE
关键词
D O I
10.1210/me.10.6.713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone loss observed in postmenopausal women is clearly associated with a decrease in estrogen levels. Interleukin 6 (IL-6), a multifunctional cytokine involved in osteoclast differentiation, is secreted by osteoblasts and appears to be a key molecule in the osteoporotic process. As previous reports have shown that the human IL-6 promoter is inhibited by estradiol, we investigated the mechanism of estradiol (E(2))-mediated IL-6 inhibition in human cells. Analysis of the IL-6 secretion as a function of time in osteoblastoma Saos-2 cells, using an IL-6 ELISA test, showed that a maximal E(2) inhibition of tumor necrosis factor-alpha (TNF alpha) induction could be monitored between 2 and 24 h of treatment. IL-6 inhibition was clearly estrogen agonist-specific in Saos-2 and MCF7 cells. Transient transfections of HeLa cells with a pIL-6/CAT plasmid and an estrogen receptor (human ER) expression vector, confirmed the role of the human ER in inhibition of the IL-6 promoter. Deletion and mutational analysis of the promoter highlighted the role of the -185/-60 region and showed that in both MCF7 and HeLa cells, the nuclear factor-IL 6 (NF-IL6) site cooperates with the nuclear factor-kappa B (NF-kappa B) motif to produce maximal induction by TNF alpha, whereas the CCAAT/enhancer-binding protein (C/EBP) site displayed different cooperative effects toward NF-kappa B depending on the cell line used. In HeLa cells, but not in MCF7 cells, we defined an essential role for the C/EBP site by showing that the E(2) sensitivity was clearly dependent on its integrity. In these cell lines, the NF-kappa B site mutation abrogated both the TNF alpha- and E(2)- sensitivity of the construct.
引用
收藏
页码:713 / 722
页数:10
相关论文
共 48 条
  • [11] HUMAN ESTROGEN-RECEPTOR CDNA - SEQUENCE, EXPRESSION AND HOMOLOGY TO V-ERB-A
    GREEN, S
    WALTER, P
    KUMAR, V
    KRUST, A
    BORNERT, JM
    ARGOS, P
    CHAMBON, P
    [J]. NATURE, 1986, 320 (6058) : 134 - 139
  • [12] STRUCTURAL-ANALYSIS OF THE SEQUENCE CODING FOR AN INDUCIBLE 26-KDA PROTEIN IN HUMAN-FIBROBLASTS
    HAEGEMAN, G
    CONTENT, J
    VOLCKAERT, G
    DERYNCK, R
    TAVERNIER, J
    FIERS, W
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03): : 625 - 632
  • [13] BIOLOGICAL AND CLINICAL ASPECTS OF INTERLEUKIN-6
    HIRANO, T
    AKIRA, S
    TAGA, T
    KISHIMOTO, T
    [J]. IMMUNOLOGY TODAY, 1990, 11 (12): : 443 - 449
  • [14] CYTOKINES AND ESTROGEN IN BONE - ANTI-OSTEOPOROTIC EFFECTS
    HOROWITZ, MC
    [J]. SCIENCE, 1993, 260 (5108) : 626 - 627
  • [15] ISHIMI Y, 1990, J IMMUNOL, V145, P3297
  • [16] INCREASED OSTEOCLAST DEVELOPMENT AFTER ESTROGEN LOSS - MEDIATION BY INTERLEUKIN-6
    JILKA, RL
    HANGOC, G
    GIRASOLE, G
    PASSERI, G
    WILLIAMS, DC
    ABRAMS, JS
    BOYCE, B
    BROXMEYER, H
    MANOLAGAS, SC
    [J]. SCIENCE, 1992, 257 (5066) : 88 - 91
  • [17] INTERLEUKIN-6 AN ENDOCRINE CYTOKINE
    JONES, TH
    [J]. CLINICAL ENDOCRINOLOGY, 1994, 40 (06) : 703 - 713
  • [18] A MEMBER OF THE C/EBP FAMILY, NF-IL6-BETA, FORMS A HETERODIMER AND TRANSCRIPTIONALLY SYNERGIZES WITH NF-IL6
    KINOSHITA, S
    AKIRA, S
    KISHIMOTO, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (04) : 1473 - 1476
  • [19] KLEIN B, 1991, BLOOD, V78, P1198
  • [20] LI XX, 1991, J BIOL CHEM, V266, P15192